Osteoporosis prevention device receives FDA Breakthrough designation

Bone Health Technologies, creator of the OsteoBoost Vibration Belt that promises to reduce the risk of osteoporosis, has been granted Breakthrough Device designation by the FDA.

OsteoBoost uses proprietary vibration technology that delivers gentle mechanical stimulation to the hips and spine at a precise, individually calibrated frequency, encouraging the body to reduce bone resorption and potentially create new bone.

This localized vibration therapy's effect is to stop the progression of bone loss and prevent the onset of osteoporosis. An initial study showed that just one 30-minute treatment with OsteoBoost reduced bone loss activity in all study participants.

The initial study results were so promising that the National Institutes of Health funded a $2 million study to determine if the positive effects of OsteoBoost could be demonstrated in a longer study with a broader population. This larger, pivotal study is currently enrolling patients and is scheduled to be completed in early 2022.  

Co-founder Shane Mangrum, MD, said: “For years, I have wanted a better option for my patients with low bone density that doesn’t have the potential side effects and the inconvenience of current drug treatments. With OsteoBoost we’ve created a safe, drug-free alternative that is easy and convenient. Now my patients with osteopenia have a new way to improve their bone health and reduce their risk of fracture.”  

Derived from NASA technology which proved that mechanical stimulation of bones through vibration would improve bone health in astronauts, OsteoBoost is the first product of its kind. Localised vibration delivered via a comfortable, easy-to-use belt has the potential to change the way osteopenia and osteoporosis are prevented and treated for millions of Americans.